Related Experiment Video
Updated: Jun 10, 2026

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries
Published on: February 25, 2016
The impact of rosiglitazone on nitric oxide bioavailability and endothelial function
Kumar Perampaladas1, John D Parker, Tommaso Gori
1Division of Cardiology, Mount Sinai and University Health Network Hospitals, University of Toronto, Toronto, Canada.
Abstract:
Clinical studies have demonstrated that rosiglitazone can improve vascular function in patients with diabetes mellitus. It remains unclear whether this effect depends on a direct improvement in endothelial function or whether it is mediated by the drug's effect on glycemic control. Yet, rosiglitazone has been linked to serious cardiovascular events. A number of studies recently investigated whether rosiglitazone affects endothelial function in healthy volunteers and patients with cardiovascular disease. Controversial observations have been reported; the observation that rosiglitazone might in certain cases impair endothelial function may suggest a mechanistic explanation for the observation of increased cardiovascular events in patients treated with rosiglitazone who have underlying cardiovascular disease. These studies are summarized and discussed in the present paper.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: Glinides
Nitric Oxide Signaling Pathway
Dipeptidyl Peptidase 4 Inhibitors
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Bioavailability: Influencing Factors

